Literature DB >> 19755521

Urotensin II induces rat cardiomyocyte hypertrophy via the transient oxidization of Src homology 2-containing tyrosine phosphatase and transactivation of epidermal growth factor receptor.

Ju-Chi Liu1, Cheng-Hsien Chen, Jin-Jer Chen, Tzu-Hurng Cheng.   

Abstract

Urotensin II (U-II) is implicated in cardiomyocyte hypertrophy, which results in cardiac remodeling. We recently demonstrated that both reactive oxygen species (ROS) generation and epidermal growth factor receptor (EGFR) transactivation play critical roles in U-II signal transduction. However, the detailed intracellular mechanism(s) underlying cardiac hypertrophy and remodeling remain unclear. In this study, we used rat cardiomyocytes treated with U-II to investigate the association between ROS generation and EGFR transactivation. U-II treatment was found to stimulate cardiomyocyte hypertrophy through phosphorylation of EGFR and ROS generation. Apocynin, an NAD(P)H oxidase inhibitor, and N-acetyl cysteine (NAC), an ROS scavenger, both inhibited EGFR transactivation induced by U-II. In contrast, 4-(3'-chloroanilino)-6,7-dimethoxy-quinazoline (AG1478, an EGFR inhibitor) failed to inhibit intracellular ROS generation induced by U-II. Src homology 2-containing tyrosine phosphatase (SHP-2), but not protein tyrosine phosphatase 1B (PTP 1B), was shown to be associated with EGFR during U-II treatment by EGFR coimmunoprecipitation. ROS have been reported to transiently oxidize the catalytic cysteine of phosphotyrosine phosphatases, subsequently inhibiting their activity. We examined the effect of U-II on SHP-2 and PTP 1B in cardiomyocytes using a modified malachite green phosphatase assay. SHP-2, but not PTP 1B, was transiently oxidized during U-II treatment, which could be repressed by NAC treatment. In SHP-2 knockdown cells, U-II-induced phosphorylation of EGFR and myocyte hypertrophy were dramatically elevated, and these effects were not influenced by NAC. Our data suggest that U-II-mediated ROS generation can transiently inhibit SHP-2 activity, thereby facilitating EGFR transactivation and hypertrophic signal transduction in rat cardiomyocytes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19755521     DOI: 10.1124/mol.109.058297

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  13 in total

1.  The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy.

Authors:  K S Oh; J H Lee; K Y Yi; C J Lim; S Lee; C H Park; H W Seo; B H Lee
Journal:  Br J Pharmacol       Date:  2015-03-26       Impact factor: 8.739

Review 2.  Cardiac GPCR-Mediated EGFR Transactivation: Impact and Therapeutic Implications.

Authors:  Laurel A Grisanti; Shuchi Guo; Douglas G Tilley
Journal:  J Cardiovasc Pharmacol       Date:  2017-07       Impact factor: 3.105

3.  GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo.

Authors:  D J Behm; N V Aiyar; A R Olzinski; J J McAtee; M A Hilfiker; J W Dodson; S E Dowdell; G Z Wang; K B Goodman; C A Sehon; M R Harpel; R N Willette; M J Neeb; C A Leach; S A Douglas
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

4.  The network map of urotensin-II mediated signaling pathway in physiological and pathological conditions.

Authors:  D A B Rex; G P Suchitha; Akhina Palollathil; Anagha Kanichery; T S Keshava Prasad; Shobha Dagamajalu
Journal:  J Cell Commun Signal       Date:  2022-02-16       Impact factor: 5.782

5.  Temporal and gefitinib-sensitive regulation of cardiac cytokine expression via chronic β-adrenergic receptor stimulation.

Authors:  Laurel A Grisanti; Ashley A Repas; Jennifer A Talarico; Jessica I Gold; Rhonda L Carter; Walter J Koch; Douglas G Tilley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-12-05       Impact factor: 4.733

6.  Contractile responses to rat urotensin II in resting and depolarized basilar arteries.

Authors:  Cristina Porras-González; Juan Ureña; Juan José Egea-Guerrero; Elena Gordillo-Escobar; Francisco Murillo-Cabezas; María del Carmen González-Montelongo; María Angeles Muñoz-Sánchez
Journal:  J Physiol Biochem       Date:  2013-10-18       Impact factor: 4.158

7.  The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer.

Authors:  Ozan Balakan; Mehmet Emin Kalender; Ali Suner; Beyhan Cengiz; Serdar Oztuzcu; Recep Bayraktar; Ersin Borazan; Taner Babacan; Celaletdin Camci
Journal:  Med Sci Monit       Date:  2014-08-12

8.  Urotensin II induces interleukin 8 expression in human umbilical vein endothelial cells.

Authors:  Chung-Yi Lee; Yi-Tin Tsai; Shih-Hurng Loh; Ju-Chi Liu; Tso-Hsiao Chen; Hung-Hsing Chao; Tzu-Hurng Cheng; Jin-Jer Chen
Journal:  PLoS One       Date:  2014-02-21       Impact factor: 3.240

9.  Lycopene Inhibits Urotensin-II-Induced Cardiomyocyte Hypertrophy in Neonatal Rat Cardiomyocytes.

Authors:  Hung-Hsing Chao; Li-Chin Sung; Cheng-Hsien Chen; Ju-Chi Liu; Jin-Jer Chen; Tzu-Hurng Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2014-05-25       Impact factor: 2.629

10.  Potential Markers in Cardiac Hypertrophy?

Authors:  Bartosz Malinowski; Gabriele Fulgheri; Michal Wicinski; Elzbieta Grzesk; Grazyna Odrowaz-Sypniewska; Grzegorz Grześk; Nasser Darwish
Journal:  EJIFCC       Date:  2012-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.